PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or ...

PTC Therapeutics draws market attention after a stronger quarterly update highlights rare disease focus and healthcare sector ...

PTC Inc. (NASDAQ:PTC) just released its latest quarterly results and things are looking bullish. PTC beat earnings, with ...

Tanla Platforms Ltd (NSE:TNSL), and PTC India Ltd (NSE:PTCI) have emerged among the stronger performers this month, rewarding ...

Strong quarterly beat: PTC outperformed analyst expectations on both revenue and profit, driven by demand for AI-enabled design and lifecycle management tools. AI at the core: The company is embedding ...

First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise - - Global Sephience (sepiapterin) ...

Q1 2026 earnings call recap: record revenue, raised 2026 guidance, Sephience launch momentum, Japan entry & pipeline ...

Private capital is pouring into artificial intelligence while promised large-scale job growth has yet to materialize, highlighting a gap between political pledges and market trends. Manufacturing and ...

PTC (NASDAQ:PTC), latest market move reflects stronger interest in industrial technology companies with recurring software ...

PTC Inc on Wednesday raised its full-year revenue forecast, citing continued demand from manufacturers ​using its software to digitize their design ‌and production processes.

The Federal Railroad Administration (FRA) is developing a new rulemaking that would streamline the regulatory process for ...